Zhengye Biotechnology regains Nasdaq compliance with $1 minimum bid price rule
Reuters2026/08/06 12:01- Zhengye Biotechnology regained compliance with Nasdaq’s $1 minimum bid-price rule, removing the risk of a delisting process tied to the deficiency.
- Nasdaq confirmed the shares closed at $1 or higher for 10 consecutive sessions from July 20 to Aug. 4, following a May 29 notice.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Universal Insurance Executive Chairman Sean P. Downes sells USD 879,562 of common shares
Anthropic IPO Wealth Bonanza Sparks Battle: Goldman Sachs, Bank of America, and Others Compete for Employee Wealth Management Business
Anthropic's valuation has soared dramatically in a very short period, and some employees who have held equity for just two years may be facing wealth realization on a scale far beyond expectations. Wealth management professionals remarked, “It’s like winning the lottery.” Currently, Goldman Sachs, Bank of America, BNY Mellon, JPMorgan, and Wells Fargo have all reached out to Anthropic, aiming to establish long-term wealth management relationships with these newly wealthy tech elites at an early stage.
Box Insider Sold Shares Worth $513,660, According to a Recent SEC Filing
Titan Logix grants 750,000 stock options to CEO, CFO at $0.53 per share
Crypto prices
More
